With the rapid and ongoing global growth of cell and gene (C&G) products, there is an opportunity for Australia to be a regional C&G hub. This report was commissioned by AusBiotech and delivered by Biointelect to build on 2021’s Regenerative Medicines Consortium Programme and produce a National Blueprint for the strategic growth and development of an Australian C&G manufacturing ecosystem. Key recommendations from this project include fostering a skilled local workforce, streamlining market access and patient delivery, and strategically expanding our translational and commercial capabilities to meet the increasing demands of the global market.
AMR’s Implications for Australia and Globally: A review of recent pivotal initiatives
This summary explores how antimicrobial resistance (AMR) is framed within
